Cogent Biosciences Inc. has disclosed prodrugs and their active metabolites acting as GTPase KRAS and their mutant inhibitors reported to be useful for the treatment of cancer.
Jazz Pharmaceuticals Ireland Ltd. has identified compounds acting as GTPase KRAS and its mutant inhibitors reported to be useful for the treatment of cancer.
Suzhou Zion Pharma Technology Co Ltd. has identified KRAS inhibitors, in particular GTPase KRAS G12D mutant and/or G13D mutant, reported to be useful for the treatment of cancer.
Kumquat Biosciences Inc. has described compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have described GTPase KRAS (G12D mutant) and/or KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer.
Scientists at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) and/or (G13D mutant) inhibitors reported to be useful for the treatment of cancer.
Newave Pharmaceutical LLC has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
